FRX — Fennec Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- CA$331.92m
- CA$325.81m
- $47.54m
- 28
- 25
- 62
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.2 | ||
| PEG Ratio (f) | 0.2 | ||
| EPS Growth (f) | 544.73% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.51% | ||
| Return on Equity | n/a | ||
| Operating Margin | -38.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.17 | n/a | 1.53 | 21.25 | 47.54 | 48.2 | 73.98 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +400 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Directors
- Khalid Islam NEC (65)
- Rostislav Raykov CEO
- Robert Andrade CFO (44)
- Shubh Goel OTH (47)
- Marco Brughera IND (65)
- Jodi Cook IND
- Adrian Haigh IND (61)
- Chris Rallis IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 25th, 2011
- Public Since
- June 5th, 2001
- No. of Employees
- 36
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 27,618,743
- Address
- 68 Tw Alexander Dr, RESEARCH TRIANGLE PARK, 27709
- Web
- https://fennecpharma.com/
- Phone
- +1 9196364530
- Auditors
- Haskell & White LLP
Upcoming Events for FRX
Q3 2025 Fennec Pharmaceuticals Inc Earnings Release
Similar to FRX
Aptose Biosciences
Toronto Stock Exchange
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
FAQ
What is the Fennec Pharmaceuticals share price?
As of Today at 20:36 UTC, shares in Fennec Pharmaceuticals are trading at CA$12.10. This share price information is delayed by 15 minutes.
How has the Fennec Pharmaceuticals share price performed this year?
Shares in Fennec Pharmaceuticals last closed at CA$12.10 and the price had moved by +35.96% over the past 365 days. In terms of relative price strength the Fennec Pharmaceuticals share price has outperformed the Toronto Stock Exchange 300 Composite Index by +14.07% over the past year.
What are the analyst and broker recommendations for Fennec Pharmaceuticals?
There is no consensus recommendation for this security.
Find out moreWhat is the Fennec Pharmaceuticals dividend yield?
Fennec Pharmaceuticals does not currently pay a dividend.
Does Fennec Pharmaceuticals pay a dividend?
Fennec Pharmaceuticals does not currently pay a dividend.
When does Fennec Pharmaceuticals next pay dividends?
Fennec Pharmaceuticals does not currently pay a dividend.
How do I buy Fennec Pharmaceuticals shares?
To buy shares in Fennec Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fennec Pharmaceuticals?
As of the previous close price of CA$12.10, shares in Fennec Pharmaceuticals had a market capitalisation of CA$331.92m.
Where are Fennec Pharmaceuticals shares listed?
Here are the trading details for Fennec Pharmaceuticals:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: FRX
What kind of share is Fennec Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Fennec Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fennec Pharmaceuticals share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Fennec Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fennec Pharmaceuticals. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +27.9%.
As of the last closing price of CA$12.10, shares in Fennec Pharmaceuticals were trading +41.68% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fennec Pharmaceuticals PE Ratio?
The Fennec Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 17.2. The shares last closed at CA$12.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fennec Pharmaceuticals?
Fennec Pharmaceuticals' management team is headed by:
- Khalid Islam - NEC
- Rostislav Raykov - CEO
- Robert Andrade - CFO
- Shubh Goel - OTH
- Marco Brughera - IND
- Jodi Cook - IND
- Adrian Haigh - IND
- Chris Rallis - IND